US$1.50+5.6%11月13日 收盘
数据截至2026年9月30日，来自2026年11月12日提交的10-Q
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年6月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$125K | US$130K | -3.85% |
| 利润 | -US$7.9M | -US$4.6M | -72.43% |
| 每股收益 | -US$0.31 | -US$0.45 | +31.11% |
| 自由现金流 | -US$5.5M | -US$3.9M | -42.32% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
公告在开盘前或收盘后发布，因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况，反应都包含在内。
(POZ-apomorphine) SER-252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER-252 to provide CDS without skin reactions. SER-252 Registrational Study Design Overview The SER-252 study is a randomized, double-blind, placebo-controlled trial with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of sixteen; n=48) in adults with Parkinson’s disease and motor fluctuations. The registrational study is designed to evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation will be overseen by an independent Safety Monitoring Committee and the study will be conducted across sites in the U.S. and Australia.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Serina Therapeutics, Inc. 于 2026年11月12日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
Serina Therapeutics, Inc. reported on 2026年11月12日. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From Serina Therapeutics, Inc.'s results release of 2026年11月12日; its quarterly report has since been filed.
Actual
US$125K
Guided
—
No guide given
Actual
-US$0.31
Guided
—
No guide given
Actual
-US$7.9M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.